Actively Recruiting
Nivo40-AVD for Advanced Classic Hodgkin Lymphoma
Led by National Medical Research Radiological Centre of the Ministry of Health of Russia · Updated on 2025-11-26
54
Participants Needed
1
Research Sites
193 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The aim of the current trial is to evaluate the efficacy and safety of flat-dose nivolumab (40 mg) in combination with AVD in the management of patients with newly diagnosed advanced classic Hodgkin Lymphoma
CONDITIONS
Official Title
Nivo40-AVD for Advanced Classic Hodgkin Lymphoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Newly-diagnosed histologically verified advanced stage (IIB-IV as per GHSG) classic Hodgkin lymphoma
- No past history of autoimmune disease
- Age over 18 years
- Ejection fraction greater than 50%
- ECOG performance status between 0 and 4
You will not qualify if you...
- Organ failure such as creatinine over 2 times the upper limit of normal, ALT or AST over 5 times the upper limit of normal, bilirubin over 2 times the upper limit of normal, hemodynamic instability, or respiratory failure greater than Grade 1
- Uncontrolled infection
- Pregnancy
- Inability to sign informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
P. Hertsen Moscow Oncology Research Institute (MORI) for administrative and economic work - the branch of the FSBI "National Medical Research Radiological Centre" (NMRRC) of the Ministry of Health of the Russian Federation
Moscow, Russia
Actively Recruiting
Research Team
M
Mobil Akhmedov, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here